专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CO6190513A2 COMPUESTOS TETRAHIDROCICLOPENTA [B] INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS 未知
公开(公告)号：CO6190513A2
公开(公告)日：2010-08-19
申请号：CO09050693
申请日：2009-05-18
申请人： LILLY CO ELI
发明人： GAVARDINAS KONSTANTINOS , GREEN JONATHAN , JADHAV PRABHAKAR KONDAJI , MATTHEWS DONALD PAUL
IPC分类号： A61K31/404 , A61P9/04 , A61P9/10 , C07D209/58
摘要： 1.- Un compuesto de Fórmula (I)caracterizado porque el centro de carbono "C*" puede estar en la configuración R, S o R/S; R1 representa ciano, -CH=NOCH3, -OCHF2, o -OCF3; R2 representa -COR2a o -SO2R2b; R2a representa alquilo (C1-C4) alcoxi (C1-C4) ciclopropilo, o NRaRb; R2b representa alquilo (C1-C4), ciclopropilo, o -NRaRb; Ra y Rb representa independientemente en cada caso H o alquilo (C1-C4); yR3 representa un grupo heteroarilo seleccionado a partir del grupo que consiste de piridinilo, pirimidinilo, pirazinilo, piridazinilo, tiazolilo, isotiazolilo y tiadiazolilo, cada uno de los cuales es opcionalmente sustituido con 1 o 2 sustituyentes, seleccionados independientemente a partir del grupo que consiste de metilo, etilo, bromo, cloro, fluoro, -CHF2-, -CF3, hidroxi, amino y -NHCH2CO2H, o una sal del mismo farmacéuticamente aceptable. 2.- El compuesto o sal de conformidad con la Reivindicación 1, caracterizado porque R1 representa ciano, o CH=NOCH3. 3.- El compuesto o sal de conformidad con la Reivindicación 2, caracterizado porque R1 representa ciano. 4.- Un compuesto o sal de conformidad con cualquiera de las Reivindicaciones 1-3, caracterizado porque R2a representa alquilo (C1-C4), alcoxi (C1-C4), ciclopropilo, o -N(CH3)2 y R2b representa alquilo (C1-C4), ciclopropilo, -N(CH3)2 o -N(C2H5)2. 5.- El compuesto o sal de conformidad con la Reivindicación 4, caracterizado porque R2 representa -COR2a y R2a representa etilo, isopropilo, metoxi, etoxi, propoxi, isopropoxi, isobutoxi, terc-butoxi, ciclopropilo, o -N(CH3)2. 6.- El compuesto o sal de conformidad con la Reivindicación 5, caracterizado porque R2a representa isopropoxi. 7.- El compuesto o sal de conformidad con la Reivindicación 4, caracterizado porque R2 representa SO2R2b y R2b representa metilo, etilo, propilo, ciclopropilo, -N(CH3)2 o -N(C2H5)2.

2. 发明专利

AT457979T 未知
公开(公告)号：AT457979T
公开(公告)日：2010-03-15
申请号：AT06785258
申请日：2006-06-21
申请人： LILLY CO ELI
发明人： FALES KEVIN , GREEN JONATHAN , JADHAV PRABHAKAR , MATTHEWS DONALD , NEEL DAVID , SMITH EDWARD
IPC分类号： C07D209/88 , C07D401/04 , C07D401/14 , C07D403/04 , C07D417/04 , C07D417/06 , C07D417/14 , C07D491/04
摘要： The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).

3. 发明专利

AT399163T 未知
公开(公告)号：AT399163T
公开(公告)日：2008-07-15
申请号：AT04811084
申请日：2004-12-08
申请人： LILLY CO ELI
发明人： GAVARDINAS KONSTANTINOS , GREEN JONATHAN , JADHAV PRABHAKAR , MATTHEWS DONALD
IPC分类号： C07D405/06 , A61K31/4184 , A61K31/454 , A61K31/5377 , C07D235/26 , C07D405/14
摘要： The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

4. 发明专利

AT382043T 未知
公开(公告)号：AT382043T
公开(公告)日：2008-01-15
申请号：AT04709806
申请日：2004-02-10
申请人： LILLY CO ELI
发明人： CONNER SCOTT , GOSSETT LYNN , GREEN JONATHAN , JONES WINTON , MANTLO NATHAN , MATTHEWS DONALD , MAYHUGH DANIEL , SMITH DARYL , VANCE JENNIFER , WANG XIAODONG , WARSHAWSKY ALAN , WINNEROSKI LEONARD , XU YANPING , ZHU GUOXIN
IPC分类号： C07D333/62 , A61K31/00 , A61K45/06 , C07C311/13 , C07C311/16 , C07C311/17 , C07C311/19 , C07C311/29 , C07C317/14 , C07C323/49 , C07C323/52 , C07D207/08 , C07D209/08 , C07D209/48 , C07D213/64 , C07D213/71 , C07D213/74 , C07D215/36 , C07D231/12 , C07D231/18 , C07D263/32 , C07D271/12 , C07D277/36 , C07D307/79 , C07D307/82 , C07D319/18 , C07D333/34 , C07D409/04 , C07D409/12 , C07D413/04
摘要： The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

5. 发明专利

AT432257T 未知
公开(公告)号：AT432257T
公开(公告)日：2009-06-15
申请号：AT03810038
申请日：2003-06-13
申请人： LILLY CO ELI
发明人： COGHLAN MICHAEL , GREEN JONATHAN , GRESE TIMOTHY , JADHAV PRABHAKAR , MATTHEWS DONALD , STEINBERG MITCHELL , FALES KEVIN , BELL MICHAEL
IPC分类号： C07C311/08 , C07D295/08 , A61K31/015 , A61K31/03 , A61K31/04 , A61K31/045 , A61K31/055 , A61K31/09 , A61K31/10 , A61K31/18 , A61K31/335 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/435 , A61K31/4402 , A61K31/4406 , A61K31/4436 , A61K31/4453 , A61K31/4965 , A61K31/5377 , A61K31/55 , A61K31/553 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/08 , A61P3/10 , A61P3/12 , A61P3/14 , A61P5/26 , A61P5/38 , A61P5/46 , A61P7/04 , A61P7/10 , A61P9/00 , A61P9/02 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P17/10 , A61P19/02 , A61P19/10 , A61P25/02 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07C22/04 , C07C22/08 , C07C25/22 , C07C25/24 , C07C33/38 , C07C39/17 , C07C39/23 , C07C39/42 , C07C43/215 , C07C43/225 , C07C43/23 , C07C47/548 , C07C47/57 , C07C49/835 , C07C205/06 , C07C205/35 , C07C211/32 , C07C211/45 , C07C215/76 , C07C217/84 , C07C233/07 , C07C233/65 , C07C233/84 , C07C235/16 , C07C251/40 , C07C251/48 , C07C255/50 , C07C261/04 , C07C271/14 , C07C275/28 , C07C307/10 , C07C311/03 , C07C311/09 , C07C311/16 , C07C311/20 , C07C311/21 , C07C311/29 , C07C317/14 , C07C317/32 , C07C321/28 , C07C323/49 , C07D209/08 , C07D209/34 , C07D211/18 , C07D213/127 , C07D213/16 , C07D213/65 , C07D213/73 , C07D213/76 , C07D213/81 , C07D221/16 , C07D223/20 , C07D231/12 , C07D231/18 , C07D233/26 , C07D233/64 , C07D233/84 , C07D235/14 , C07D235/26 , C07D241/12 , C07D241/20 , C07D241/26 , C07D261/08 , C07D263/52 , C07D263/56 , C07D263/58 , C07D277/60 , C07D295/092 , C07D295/22 , C07D295/26 , C07D313/12 , C07D313/14 , C07D333/80 , C07D337/12 , C07D337/14 , C07D401/06 , C07D403/06 , C07D405/04 , C07D405/06 , C07D409/04 , C07D471/04 , C07D487/04 , C07D491/044
摘要： The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式